This post was originally published on this site
© Reuters.Investing.com — Here is a roundup of regulatory releases from the London Stock Exchange on Friday, 8th November. Please refresh for updates.
- International Consolidated Airlines Group (LON:), the parent of British Airways, Iberia and Aer Lingus, said it’s cutting its medium-term target for earnings per share growth to at least 10% from at least 12% previously.
- That reflects a reduced forecast for capacity growth: the group now sees available seat-kilometers rising only 3.4% a year through 2023 from a previous estimate of 6%.
- It’s also changing the way it reports capital expenditure, stripping out any proceeds from sale of property, plant and equipment and intangible assets. As such, the new, ‘gross’ annual capex requirement is seen at an average of 4.7 billion euros ($5.2 billion), whereas the old ‘net’ capex spend had been estimated at 2.6 billion euros.
- The estimate for levered free cash flow remained the same at 2.1 billion euros a year, while leverage is still to be contained at or below 1.8 times EBITDA.
-
- IAG’s passenger traffic growth slowed in October to 3.4%
- Pharma group AstraZeneca (LON:) reported successful Phase III trials for its roxadustat drug, used to treat anemia in patients suffering from chronic kidney disease.
- It said it expects to make a regulatory submission for the drug to be approved in the U.S. by year-end.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
